表紙
市場調查報告書

微創生檢技術的全球市場 - 分析與預測:2019-2030年

Global Minimally Invasive Biopsy Technologies Market: - Analysis and Forecast, 2019-2030

出版商 BIS Research Inc. 商品編碼 929180
出版日期 內容資訊 英文 270 Pages
商品交期: 最快1-2個工作天內
價格
微創生檢技術的全球市場 - 分析與預測:2019-2030年 Global Minimally Invasive Biopsy Technologies Market: - Analysis and Forecast, 2019-2030
出版日期: 2020年02月25日內容資訊: 英文 270 Pages
簡介

全球微創生檢技術市場規模在2019年∼2030年的預測期間內,預計將以12.82%的年複合成長率成長。該市場的收益在2018年為9億2,480萬美金。市場規模至2030年預計將達40億3,000萬美元。

本報告涵括全球微創生檢技術市場,提供市場動態,競爭環境,各市場區隔、各地區的市場,競爭情形,及主要企業等相關之詳細分析。

摘要整理

第1章 產品定義

第2章 調查範圍

第3章 調查手法

第4章 產業分析

  • 產業生態系統
  • 法律規範、政府措施
  • 專利分析
  • 醫生的認識

第5章 競爭情形

  • 主要策略、發展
  • 市場佔有率分析
  • 成長佔有率分析

第6章 微創生檢技術的全球市場

  • 前提條件、限制事項
  • 主要調查結果、機會評估
  • 全球微創生檢技術:市場方案
  • 市場估計手法

第7章 微創生檢技術的全球市場:各技術

  • 概要
  • 全球液態生檢市場方案
  • 全球光學生檢市場方案
  • 全球及其他技術市場方案

第8章 微創生檢技術的全球市場:各地區

  • 概要、主要調查結果
  • 北美
    • 市場
    • 液態生檢市場
    • 光學生檢市場
    • 其他技術市場
  • 歐洲
  • 亞太地區
  • 南美、中東
  • 其他地區

第9章 企業簡介

  • Abcodia Ltd.
  • Adaptive Biotechnologies
  • Biocept, Inc.
  • Caliber Imaging & Diagnostics
  • Chronix Biomedical
  • DermTech
  • F. Hoffmann-La Roche Ltd
  • Guardant Health, Inc.
  • Mauna Kea Technologies
  • Myriad Genetics
  • NeoGenomics Laboratories, Inc.
  • Owlstone Medical Ltd
  • QIAGEN
  • Thermo Fisher Scientific
  • Veracyte, Inc.
目錄
Product Code: BH200A

Global Minimally Invasive Biopsy Technologies Market to Reach $4.03 Billion by 2030

Key Questions Answered in the Report:

  • What are the various minimally invasive biopsy technologies available in the market?
  • What are the major market drivers, challenges, and opportunities in the global minimally invasive biopsy technologies market?
  • What is the current market size and future potential of these technologies?
  • How is the integration of AI expected to impact the market growth during the forecast period?
  • What is the role of minimally invasive biopsy technologies in drug discovery and clinical research?
  • How are minimally invasive biopsy technologies expected to drive precision medicine during the forecast period?
  • How are technologies such as optical biopsy, breath biopsy, and skin assays expected to evolve in the future?
  • What are the guidelines implemented by different government bodies to regulate the approval of minimally invasive biopsy technologies?
  • Which are the established as well as emerging players in this market and what key strategies are being followed by them to establish a strong foothold in the market?
  • Which therapeutic application market is estimated to witness massive incorporation of the minimally invasive biopsy technologies market in the forecast period?
  • Which clinical application is expected to dominate the market during the forecast period?
  • Which technological advancements are expected to impact the market growth in the future?

Global Minimally Invasive Biopsy Technologies Market Forecast, 2019-2030

The minimally invasive biopsy technologies market industry analysis by BIS Research projects the market to grow at a significant CAGR of 12.82% during the forecast period, 2019-2030. The minimally invasive biopsy technologies market generated $924.8 million revenue in 2018, in terms of value.

The market growth in the minimally invasive biopsy technologies market can primarily be attributed to the factors such increasing global burden of cancer, rising awareness for early disease diagnosis, and increasing demand for minimally invasive diagnostics. However, there are significant challenges which are restraining the market growth. These challenges include stringent regulatory guidelines, the high cost of technologies, and the lack of adequate reimbursement policies.

Expert Quote

"The increasing adoption of targeted therapies and the growing prominence of the concept of personalized medicine are driving the adoption of minimally invasive biopsy technologies. The increasing adoption is further expected to bring down the cost and is expected to improve the patient access to these technologies."

Scope of the Market Intelligence on Global Minimally Invasive Biopsy Technologies Market

The research report on global minimally invasive biopsy technologies market provides a holistic view of the market in terms of various factors influencing it, including regulatory reforms and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with the minimally invasive biopsy technologies market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to minimally invasive biopsy technologies market.

Market Segmentation

The global minimally invasive biopsy technologies market segmentation (on the basis of technology) is further segmented into liquid biopsy, optical biopsy, and other technologies (brush biopsy, fine needle aspiration, pigmented lesion assays, and breath biopsy).

The global liquid biopsy market is further segmented by product (tests, kits and consumables, and instruments), circulating biomarkers (ctDNA, CTCs, cfDNA, extracellular vesicles and others), clinical application (treatment monitoring, prognosis and recurrence monitoring, treatment selection, and diagnosis and screening), and therapeutic application (lung cancer, breast cancer, prostate cancer, colorectal cancer, blood cancer, other types of cancer, and non-oncology applications).

The global optical biopsy market is further segmented by therapeutic application (oncology and non-oncology applications).

The global other technologies market is further segmented by therapeutic application (lung cancer, melanoma, thyroid cancer, and non-oncology applications).

The global minimally invasive biopsy technologies market segmentation (on the basis of region) is segmented into North America, Europe, Asia-Pacific, Latin America and the Middle East, and Rest-of-the-World. The potential of each technology with respect to different regions has also been provided.

Key Companies in the Global Minimally Invasive Biopsy Technologies Market

The key manufacturers who have been contributing significantly to the global minimally invasive biopsy technologies market include Abcodia Ltd., Adaptive Biotechnologies, Biocept, Inc., Caliber Imaging & Diagnostics, Chronix Biomedical, DermTech, F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Mauna Kea Technologies, Myriad Genetics, NeoGenomics Laboratories, Inc., Owlstone Medical Ltd, QIAGEN, Thermo Fisher Scientific, and Veracyte, Inc., among others.

Table of Contents

Executive Summary

1 Product Definition

  • 1.1 Inclusions and Exclusions

2 Research Scope

  • 2.1 Scope of Work
  • 2.2 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 Global Minimally Invasive Biopsy Technologies Market: Research Methodology
    • 3.1.1 Primary Data Sources
    • 3.1.2 Secondary Data Sources
    • 3.1.3 Selection Criteria for Company Profiles

4 Industry Analysis

  • 4.1 Industry Ecosystem
  • 4.2 Regulatory Framework and Government Initiatives
    • 4.2.1 Liquid Biopsy: Regulatory Framework
      • 4.2.1.1 Liquid Biopsy: Regulations in the U.S.
      • 4.2.1.2 Liquid Biopsy: Regulations in Other Countries
    • 4.2.2 Optical Biopsy and Other Technologies: Regulatory Framework
      • 4.2.2.1 Optical Biopsy and Other Technologies: Regulations in the U.S.
      • 4.2.2.2 Optical Biopsy and Other Technologies: Regulations in the Europe
      • 4.2.2.3 Optical Biopsy and Other Technologies: Regulations in Other Countries
  • 4.3 Patent Analysis
    • 4.3.1 Liquid Biopsy: Patent Analysis
    • 4.3.2 Optical Biopsy: Patent Analysis
  • 4.4 Physician's Perception

5 Competitive Landscape

  • 5.1 Key strategies and Developments
    • 5.1.1 Partnerships, Alliances, and Business Expansions
    • 5.1.2 New Offerings
    • 5.1.3 Funding Activities
    • 5.1.4 Procurement and Sales Agreements
    • 5.1.5 Regulatory and Legal Developments
    • 5.1.6 Mergers and Acquisitions
  • 5.2 Market Share Analysis
    • 5.2.1 Market Share Analysis: Global Liquid Biopsy Market
    • 5.2.2 Market Share Analysis: Global Optical Biopsy Market
    • 5.2.3 Market Share Analysis: Global Other Technologies Market
  • 5.3 Growth Share Analysis
    • 5.3.1 Growth Share Matrix (by Technology)
    • 5.3.2 Growth Share Matrix (by Therapeutic Application)
    • 5.3.3 Growth Share Matrix (by Region)

6 Global Minimally Invasive Biopsy Technologies Market, 2018-2030

  • 6.1 Assumptions and Limitations
  • 6.2 Key Findings and Opportunity Assessment
  • 6.3 Global Minimally Invasive Biopsy Technologies, Market Scenario
    • 6.3.1 Global Minimally Invasive Biopsy Technologies Market Size and Forecast (2018-2030)
    • 6.3.2 Market Dynamics
      • 6.3.2.1 Overview
      • 6.3.2.2 Impact Analysis
      • 6.3.2.3 Market Drivers
        • 6.3.2.3.1 Rising Global Burden of Cancer
        • 6.3.2.3.2 Increasing Number of Cross-Industry Collaborations
        • 6.3.2.3.3 Growing Prominence of Precision Medicine
      • 6.3.2.4 Market Restraints
        • 6.3.2.4.1 Uncertain Regulatory Requirements
        • 6.3.2.4.2 Lack of Favorable Reimbursement Policies
        • 6.3.2.4.3 Technical Challenges Associated with the Analysis of Circulating Biomarkers
      • 6.3.2.5 Market Opportunities
        • 6.3.2.5.1 Business Expansion in Emerging Economies
        • 6.3.2.5.2 Integration of Artificial Intelligence (AI)
        • 6.3.2.5.3 Rising Number of Initiatives by the Government
  • 6.4 Market Estimation Method

7 Global Minimally Invasive Biopsy Technologies Market, by Technology, 2018-2030

  • 7.1 Overview
  • 7.2 Global Liquid Biopsy Market Scenario, 2018-2030
    • 7.2.1 Principle and Advantages of Liquid Biopsy
    • 7.2.2 Key Findings and Opportunity Assessment
    • 7.2.3 Global Liquid Biopsy Market, Market Size and Forecast (2018-2030)
      • 7.2.3.1 Market Dynamics
        • 7.2.3.1.1 Impact Analysis
        • 7.2.3.1.2 Market Drivers
          • 7.2.3.1.2.1 Increasing Demand for Liquid Biopsy Tests
          • 7.2.3.1.2.2 Recent Product Launches and Approvals
          • 7.2.3.1.2.3 Strong Pipeline
        • 7.2.3.1.3 Market Restraints
          • 7.2.3.1.3.1 Uncertain Regulatory Requirements
          • 7.2.3.1.3.2 Lack of Adequate Reimbursement
    • 7.2.4 Global Liquid Biopsy Market Segmentation
      • 7.2.4.1 Global Liquid Biopsy Market (by Product), 2018-2030
        • 7.2.4.1.1 Overview
        • 7.2.4.1.2 Tests
        • 7.2.4.1.3 Kits and Consumables
        • 7.2.4.1.4 Instruments
      • 7.2.4.2 Global Liquid Biopsy Market, by Circulating Biomarker, Market Size and Forecast (2018-2030)
        • 7.2.4.2.1 Overview
        • 7.2.4.2.2 Circulating Tumor DNA (ctDNA)
        • 7.2.4.2.3 Circulating Tumor Cells (CTCs)
        • 7.2.4.2.4 Cell-Free DNA (cfDNA)
        • 7.2.4.2.5 Extracellular Vesicles and Others
      • 7.2.4.3 Global Liquid Biopsy Market, by Clinical Application, Market Size and Forecast (2018-2030)
        • 7.2.4.3.1 Overview
        • 7.2.4.3.2 Treatment Monitoring
        • 7.2.4.3.3 Prognosis and Recurrence Monitoring
        • 7.2.4.3.4 Treatment Selection
        • 7.2.4.3.5 Diagnosis and Screening
      • 7.2.4.4 Global Liquid Biopsy Market, by Therapeutic Application, Market Size and Forecast (2018-2030)
        • 7.2.4.4.1 Overview
        • 7.2.4.4.2 Lung Cancer
        • 7.2.4.4.3 Breast Cancer
        • 7.2.4.4.4 Prostate Cancer
        • 7.2.4.4.5 Colorectal Cancer
        • 7.2.4.4.6 Blood Cancer
        • 7.2.4.4.7 Other Types of Cancer
        • 7.2.4.4.8 Non-Oncology Applications
  • 7.3 Global Optical Biopsy Market Scenario, 2018-2030
    • 7.3.1 Principle and Advantages of Optical Biopsy
    • 7.3.2 Key Findings and Opportunity Assessment
    • 7.3.3 Global Optical Biopsy Market, Market Size and Forecast (2018-2030)
      • 7.3.3.1 Market Dynamics
        • 7.3.3.1.1 Impact Analysis
        • 7.3.3.1.2 Market Drivers
          • 7.3.3.1.2.1 Recent Product Launches and Approvals
          • 7.3.3.1.2.2 Significant Number of Funding and Investments
          • 7.3.3.1.2.3 Anticipated Product Launches
        • 7.3.3.1.3 Market Restraints
          • 7.3.3.1.3.1 Lack of Favorable Reimbursement
          • 7.3.3.1.3.2 Stringent Regulatory Guidelines
    • 7.3.4 Global Optical Biopsy Market (by Therapeutic Application), 2018-2030
      • 7.3.4.1 Overview
      • 7.3.4.2 Oncology
      • 7.3.4.3 Non-Oncology Applications
  • 7.4 Global Other Technologies Market Scenario, 2018-2030
    • 7.4.1 Overview
    • 7.4.2 Key Findings and Opportunity Assessment
    • 7.4.3 Global Other Technologies Market, Market Size and Forecast (2018-2030)
      • 7.4.3.1 Market Dynamics
        • 7.4.3.1.1 Impact Analysis
        • 7.4.3.1.2 Market Drivers
          • 7.4.3.1.2.1 Ongoing Strategic Collaborations and M&A Activities
          • 7.4.3.1.2.2 Strong Product Pipeline
        • 7.4.3.1.3 Market Restraints
          • 7.4.3.1.3.1 Poor Reimbursement Scenario
          • 7.4.3.1.3.2 Limited Scope of Expansion in Emerging Economies
    • 7.4.4 Global Other Technologies Market, (by Therapeutic Application)
      • 7.4.4.1 Overview
      • 7.4.4.2 Lung Cancer
      • 7.4.4.3 Melanoma
      • 7.4.4.4 Thyroid Cancer
      • 7.4.4.5 Non-Oncology Applications

8 Global Minimally Invasive Biopsy Technologies Market, (by Region), 2018-2030

  • 8.1 Overview and Key Findings
  • 8.2 North America
    • 8.2.1 Market Footprint: North America Minimally Invasive Biopsy Technologies Market
      • 8.2.1.1 Market Dynamics
        • 8.2.1.1.1 Impact Analysis
    • 8.2.2 North America: Liquid Biopsy Market
      • 8.2.2.1 North America: Liquid Biopsy Market, By Country
        • 8.2.2.1.1 U.S.
        • 8.2.2.1.2 Canada
    • 8.2.3 North America: Optical Biopsy Market
      • 8.2.3.1 North America: Optical Biopsy Market, by Country
        • 8.2.3.1.1 U.S.
        • 8.2.3.1.2 Canada
    • 8.2.4 North America: Other Technologies Market
      • 8.2.4.1 North America: Other Technologies Market, By Country
        • 8.2.4.1.1 U.S.
        • 8.2.4.1.2 Canada
  • 8.3 Europe
    • 8.3.1 Market Footprint: Europe Minimally Invasive Biopsy Technologies Market
      • 8.3.1.1 Market Dynamics
        • 8.3.1.1.1 Impact Analysis
    • 8.3.2 Europe: Liquid Biopsy Market
      • 8.3.2.1 Europe: Liquid Biopsy Market, By Country
        • 8.3.2.1.1 Germany
        • 8.3.2.1.2 France
        • 8.3.2.1.3 U.K.
        • 8.3.2.1.4 Italy
        • 8.3.2.1.5 Spain
        • 8.3.2.1.6 Rest-of-Europe
    • 8.3.3 Europe: Optical Biopsy Market
      • 8.3.3.1 Europe: Optical Biopsy Market, by Country
        • 8.3.3.1.1 Germany
        • 8.3.3.1.2 U.K.
        • 8.3.3.1.3 France
        • 8.3.3.1.4 Netherlands
        • 8.3.3.1.5 Rest-of-Europe
    • 8.3.4 Europe: Other Technologies Market
      • 8.3.4.1 Europe: Other Technologies Market, By Country
        • 8.3.4.1.1 U.K.
        • 8.3.4.1.2 Germany
        • 8.3.4.1.3 Switzerland
  • 8.4 Asia-Pacific
    • 8.4.1 Market Footprint: Asia-Pacific Minimally Invasive Biopsy Technologies Market
      • 8.4.1.1 Market Dynamics
        • 8.4.1.1.1 Impact Analysis
    • 8.4.2 Asia-Pacific: Liquid Biopsy Market
      • 8.4.2.1 Asia-Pacific: Liquid Biopsy Market, by Country
        • 8.4.2.1.1 China
        • 8.4.2.1.2 Japan
        • 8.4.2.1.3 India
        • 8.4.2.1.4 Australia
        • 8.4.2.1.5 South Korea
        • 8.4.2.1.6 Singapore
        • 8.4.2.1.7 Rest-of-Asia-Pacific
    • 8.4.3 Asia-Pacific: Optical Biopsy Market
      • 8.4.3.1 Asia-Pacific: Optical Biopsy Market, by Country
        • 8.4.3.1.1 Japan
        • 8.4.3.1.2 China
        • 8.4.3.1.3 South Korea
        • 8.4.3.1.4 Rest-of Asia-Pacific
  • 8.5 Latin America and the Middle East
    • 8.5.1 Market Footprint: Latin America and the Middle East Minimally Invasive Biopsy Technologies Market
      • 8.5.1.1 Market Dynamics
        • 8.5.1.1.1 Impact Analysis
    • 8.5.2 Latin America and the Middle East: Liquid Biopsy Market
      • 8.5.2.1 Latin America and the Middle East: Liquid Biopsy Market, By Country
        • 8.5.2.1.1 Brazil
        • 8.5.2.1.2 Mexico
        • 8.5.2.1.3 Saudi Arabia
        • 8.5.2.1.4 Rest-of-Latin America and the Middle East
    • 8.5.3 Latin America and the Middle East: Optical Biopsy Market
  • 8.6 Rest-of-the-World
    • 8.6.1 Market Footprint: Rest-of-the-World Minimally Invasive Biopsy Technologies Market
      • 8.6.1.1 Market Dynamics
        • 8.6.1.1.1 Impact Analysis
    • 8.6.2 Rest-of-the-World: Liquid Biopsy Market
    • 8.6.3 Rest-of-the-World: Optical Biopsy Market

9 Company Profiles

  • 9.1 Abcodia Ltd.
    • 9.1.1 Company Overview
    • 9.1.1 Role of Abcodia Ltd. in the Global Minimally Invasive Biopsy Technologies Market
    • 9.1.2 SWOT Analysis: Abcodia Ltd.
  • 9.2 Adaptive Biotechnologies
    • 9.2.1 Company Overview
    • 9.2.2 Role of Adaptive Biotechnologies in the Global Minimally Invasive Biopsy Technologies Market
    • 9.2.3 Financials
    • 9.2.4 SWOT Analysis: Adaptive Biotechnologies
  • 9.3 Biocept, Inc.
    • 9.3.1 Company Overview
    • 9.3.2 Role of Biocept, Inc. in the Global Minimally Invasive Biopsy Technologies Market
    • 9.3.3 Financials
    • 9.3.3.1 Key Insights on the Financial Health of the Company
    • 9.3.4 SWOT Analysis: Biocept, Inc.
  • 9.4 Caliber Imaging & Diagnostics
    • 9.4.1 Company Overview
    • 9.4.2 Role of Caliber Imaging & Diagnostics in the Global Minimally Invasive Biopsy Technologies Market
    • 9.4.3 SWOT Analysis: Caliber Imaging & Diagnostics
  • 9.5 Chronix Biomedical
    • 9.5.1 Company Overview
    • 9.5.2 Role of Chronix Biomedical in the Global Minimally Invasive Biopsy Technologies Market
    • 9.5.3 SWOT Analysis: Chronix Biomedical
  • 9.6 DermTech
    • 9.6.1 Company Overview
    • 9.6.2 Role of DermTech in the Global Minimally Invasive Biopsy Technologies Market
    • 9.6.3 Financials
      • 9.6.3.1 Key Insights on the Financial Health of the Company
    • 9.6.4 SWOT Analysis: DermTech
  • 9.7 F. Hoffmann-La Roche Ltd
    • 9.7.1 Company Overview
    • 9.7.2 Role of F. Hoffmann-La Roche Ltd in the Global Minimally Invasive Biopsy Technologies Market
    • 9.7.3 Financials
    • 9.7.3.1 Key Insights on the Financial Health of the Company
    • 9.7.4 SWOT Analysis: F. Hoffmann-La Roche Ltd
  • 9.8 Guardant Health, Inc.
    • 9.8.1 Company Overview
    • 9.8.2 Role of Guardant Health, Inc. in the Global Minimally Invasive Biopsy Technologies Market
    • 9.8.3 Financials
    • 9.8.3.1 Key Insights on the Financial Health of the Company
    • 9.8.4 SWOT Analysis: Guardant Health, Inc.
  • 9.9 Mauna Kea Technologies
    • 9.9.1 Company Overview
    • 9.9.2 Role of Mauna Kea Technologies in the Global Minimally Invasive Biopsy Technologies Market
    • 9.9.3 Financials
    • 9.9.3.1 Key Insights on the Financial Health of the Company
    • 9.9.4 SWOT Analysis: Mauna Kea Technologies
  • 9.10 Myriad Genetics
    • 9.10.1 Company Overview
    • 9.10.2 Role of Myriad Genetics in the Global Minimally Invasive Biopsy Technologies Market
    • 9.10.3 Financials
      • 9.10.3.1 Key Insights on the Financial Health of the Company
    • 9.10.4 SWOT Analysis: Myriad Genetics
  • 9.11 NeoGenomics Laboratories, Inc.
    • 9.11.1 Company Overview
    • 9.11.2 Role of NeoGenomics Laboratories, Inc. in the Global Minimally Invasive Biopsy Technologies Market
    • 9.11.3 Financials
      • 9.11.3.1 Key Insights on the Financial Health of the Company
    • 9.11.4 SWOT Analysis: NeoGenomics Laboratories, Inc.
  • 9.12 Owlstone Medical Ltd
    • 9.12.1 Company Overview
    • 9.12.2 Role of Owlstone Medical Ltd in the Global Minimally Invasive Biopsy Technologies Market
    • 9.12.3 SWOT Analysis: Owlstone Medical Ltd
  • 9.13 QIAGEN
    • 9.13.1 Company Overview
    • 9.13.2 Role of QIAGEN in the Global Minimally Invasive Biopsy Technologies Market
    • 9.13.3 Financials
      • 9.13.3.1 Key Insights on the Financial Health of the Company
    • 9.13.4 SWOT Analysis: QIAGEN
  • 9.14 Thermo Fisher Scientific
    • 9.14.1 Company Overview
    • 9.14.2 Role of Thermo Fisher Scientific in the Global Minimally Invasive Biopsy Technologies Market
    • 9.14.3 Financials
      • 9.14.3.1 Key Insights on the Financial Health of the Company
    • 9.14.4 SWOT Analysis: Thermo Fisher Scientific
  • 9.15 Veracyte, Inc.
    • 9.15.1 Company Overview
    • 9.15.2 Role of Veracyte, Inc. in the Global Minimally Invasive Biopsy Technologies Market
    • 9.15.3 Financials
      • 9.15.3.1 Key Insights on the Financial Health of the Company
    • 9.15.4 SWOT Analysis: Veracyte, Inc.

List of Tables

  • Table 4.1: Guidance Documents for the FDA Approval of Liquid Biopsies
  • Table 4.2: Regulatory Bodies in Other Countries
  • Table 6.1: Market Drivers
  • Table 6.2: Market Restraints
  • Table 6.3: Global Cancer Statistics (by Region), 2018
  • Table 6.4: National Expenditures for Cancer Care in the U.S. ($Billion)
  • Table 6.5: 5-Year Prevalence (2018) of Major Cancer Types
  • Table 7.1: Market Drivers
  • Table 7.2: Market Restraints
  • Table 7.3: Liquid Biopsy: Recent Launches and Approvals
  • Table 7.4: Liquid Biopsy: Pipeline
  • Table 7.5: Market Drivers
  • Table 7.6: Market Restraints
  • Table 7.7: Optical Biopsy: Recent Launches and Approvals
  • Table 7.8: Market Drivers
  • Table 7.9: Market Restraints
  • Table 7.10: Pipeline Products
  • Table 8.1: Market Drivers
  • Table 8.2: Market Restraints
  • Table 8.3: Market Drivers
  • Table 8.4: Market Restraints
  • Table 8.6: Market Drivers
  • Table 8.7: Market Restraints
  • Table 8.8: Market Drivers
  • Table 8.9: Market Restraints
  • Table 8.10: Market Drivers
  • Table 8.11: Market Restraints

List of Figures

  • Figure 1: Global Minimally Invasive Biopsy Technologies Market, 2018-2030
  • Figure 2: Impact Analysis of Market Drivers and Market Restraints, 2018-2030
  • Figure 3: Leading Players in the Global Minimally Invasive Biopsy Technologies Market
  • Figure 4: Share of Key Developments and Strategies, January 2015-December 2019
  • Figure 2.1: Global Minimally Invasive Biopsy Technologies Market Segmentation
  • Figure 3.1: Research Methodology
  • Figure 3.2: Primary Research
  • Figure 3.3: Secondary Research
  • Figure 3.4: Data Triangulation
  • Figure 3.5: Bottom-up Approach (Segment-Wise Analysis)
  • Figure 3.6: Top-Down Approach (Segment-Wise Analysis)
  • Figure 3.7: Assumptions and Limitations
  • Figure 3.8: Considered Factors for Data Prediction and Modelling
  • Figure 3.9: Shares of Key Company Profiles
  • Figure 4.1: Industry Ecosystem
  • Figure 4.2: Evolution of FDA Guidelines for the Approval of Companion Diagnostics
  • Figure 4.3: Number of Patents in Liquid Biopsy (2011-2019)
  • Figure 4.4: Number of Patents in Optical Biopsy (2011-2019)
  • Figure 5.1: Share of Key Developments and Strategies, January 2015-December 2019
  • Figure 5.2: Share of Partnerships, Alliances and Business Expansions, January 2015-December 2019
  • Figure 5.3: Share of New Offerings, January 2015-December 2019
  • Figure 5.4: Share of Funding Activities, January 2015-December 2019
  • Figure 5.5: Share of Procurement and Sales Agreements, January 2015-December 2019
  • Figure 5.6: Share of Regulatory and Legal Developments, January 2015-December 2019
  • Figure 5.7: Share of Mergers and Acquisitions, January 2015-December 2019
  • Figure 5.8: Market Share Analysis: Global Liquid Biopsy Market, 2018
  • Figure 5.9: Market Share Analysis: Global Liquid Biopsy Market, 2017
  • Figure 5.10: Market Share Analysis: Global Optical Biopsy Market, 2018
  • Figure 5.11: Market Share Analysis: Global Optical Biopsy Market, 2018
  • Figure 5.12: Market Share Analysis: Global Other Technologies Market, 2018
  • Figure 5.13: Market Share Analysis: Global Other Technologies Market, 2017
  • Figure 5.14: Growth Share Matrix: Global Minimally Invasive Biopsy Technologies Market (by Technology), 2018-2030
  • Figure 5.15: Growth Share Matrix: Global Minimally Invasive Biopsy Technologies Market (by Therapeutic Application), 2018-2030
  • Figure 5.16: Growth Share Matrix: Global Minimally Invasive Biopsy Technologies Market (by Region), 2018-2030
  • Figure 6.1: Global Minimally Invasive Biopsy Technologies Market, 2030 Opportunity Assessment
  • Figure 6.2: Global Minimally Invasive Biopsy Technologies Market, 2018-2030
  • Figure 7.1: Global Minimally Invasive Biopsy Technologies Market (by Technology), 2018-2030
  • Figure 7.2: Global Liquid Biopsy Market, 2030 Opportunity Assessment
  • Figure 7.3: Global Liquid Biopsy Market, 2018-2030
  • Figure 7.4: Global Liquid Biopsy Market Segmentation
  • Figure 7.5: Global Liquid Biopsy Market (by Product), 2018-2030
  • Figure 7.6: Global Liquid Biopsy Market (by Tests), 2018-2030
  • Figure 7.7: Global Liquid Biopsy Market (by Kits and Consumables), 2018-2030
  • Figure 7.8: Global Liquid Biopsy Market (by Instruments), 2018-2030
  • Figure 7.9: Global Liquid Biopsy Market (by Circulating Biomarkers), 2018-2030
  • Figure 7.10: Global Liquid Biopsy Market (by ctDNA), 2018-2030
  • Figure 7.11: Global Liquid Biopsy Market (by CTCs), 2018-2030
  • Figure 7.12: Global Liquid Biopsy Market (by cfDNA), 2018-2030
  • Figure 7.13: Global Liquid Biopsy Market (by Extracellular Vesicles and Others), 2018-2030
  • Figure 7.14: Global Liquid Biopsy Market (by Clinical Application), 2018-2030
  • Figure 7.15: Global Liquid Biopsy Market (by Treatment Monitoring), 2018-2030
  • Figure 7.16: Global Liquid Biopsy Market (by Prognosis and Recurrence Monitoring), 2018-2030
  • Figure 7.17: Global Liquid Biopsy Market (by Treatment Selection), 2018-2030
  • Figure 7.18: Global Liquid Biopsy Market (by Diagnosis and Screening), 2018-2030
  • Figure 7.19: Global Liquid Biopsy Market (by Therapeutic Application), 2018-2030
  • Figure 7.20: Global Liquid Biopsy Market (by Lung Cancer), 2018-2030
  • Figure 7.21: Global Liquid Biopsy Market (by Breast Cancer), 2018-2030
  • Figure 7.22: Global Liquid Biopsy Market (by Prostate Cancer), 2018-2030
  • Figure 7.23: Global Liquid Biopsy Market (by Colorectal Cancer), 2018-2030
  • Figure 7.24: Global Liquid Biopsy Market (by Blood Cancer), 2018-2030
  • Figure 7.25: Global Liquid Biopsy Market (by Other Types of Cancer), 2018-2030
  • Figure 7.26: Global Liquid Biopsy Market (by Non-Oncology Applications), 2018-2030
  • Figure 7.27: Global Optical Biopsy Market, 2030 Opportunity Assessment
  • Figure 7.28: Global Optical Biopsy Market, 2018-2030
  • Figure 7.29: Global Optical Biopsy Market (by Therapeutic Application), 2018-2030
  • Figure 7.30: Global Optical Biopsy Market (by Oncology), 2018-2030
  • Figure 7.31: Global Optical Biopsy Market (by Oncology), 2018-2030
  • Figure 7.32: Other Technologies
  • Figure 7.33: Global Other Technologies Market, 2030 Opportunity Assessment
  • Figure 7.34: Global Other Technologies Market, 2018-2030
  • Figure 7.35: Global Other Technologies Market (by Therapeutic Application), 2018-2030
  • Figure 7.36: Global Other Technologies Market (by Lung Cancer), 2018-2030
  • Figure 7.37: Global Other Technologies Market (by Melanoma), 2018-2030
  • Figure 7.38: Global Other Technologies Market (by Thyroid Cancer), 2018-2030
  • Figure 7.39: Global Other Technologies Market (by Non-Oncology Applications), 2018-2030
  • Figure 8.1: Global Minimally Invasive Biopsy Technologies Market Scenario, 2018 and 2030
  • Figure 8.2: North America: Minimally Invasive Biopsy Technologies Market, 2018-2030
  • Figure 8.3: North America: Liquid Biopsy Market, 2018-2030
  • Figure 8.4: North America: Liquid Biopsy Market Dynamics
  • Figure 8.5: North America: Liquid Biopsy Market (by Country), 2018-2030
  • Figure 8.6: U.S.: Liquid Biopsy Market, 2018-2030
  • Figure 8.7: Canada: Liquid Biopsy Market, 2018-2030
  • Figure 8.8: North America: Optical Biopsy Market, 2018-2030
  • Figure 8.9: North America: Optical Biopsy Market Dynamics
  • Figure 8.10: North America: Optical Biopsy Market (by Country), 2018-2030
  • Figure 8.11: U.S.: Optical Biopsy Market, 2018-2030
  • Figure 8.12: Canada: Optical Biopsy Market, 2018-2030
  • Figure 8.13: North America: Other Technologies Market, 2018-2030
  • Figure 8.14: North America: Other Technologies Market Dynamics
  • Figure 8.15: North America: Other Technologies Market (by Country), 2018-2030
  • Figure 8.16: U.S.: Other Technologies Market, 2018-2030
  • Figure 8.17: Canada: Other Technologies Market, 2018-2030
  • Figure 8.18: Europe: Minimally Invasive Biopsy Technologies Market, 2018-2030
  • Figure 8.19: Europe: Liquid Biopsy Market, 2018-2030
  • Figure 8.20: Europe: Liquid Biopsy Market Dynamics
  • Figure 8.21: Europe: Liquid Biopsy Market (by Country), 2018-2030
  • Figure 8.22: Germany: Liquid Biopsy Market, 2018-2030
  • Figure 8.23: France: Liquid Biopsy Market, 2018-2030
  • Figure 8.24: U.K.: Liquid Biopsy Market, 2018-2030
  • Figure 8.25: Italy: Liquid Biopsy Market, 2018-2030
  • Figure 8.26: Spain: Liquid Biopsy Market, 2018-2030
  • Figure 8.27: Rest-of-Europe: Liquid Biopsy Market, 2018-2030
  • Figure 8.28: Europe: Optical Biopsy Market, 2018-2030
  • Figure 8.29: Europe: Optical Biopsy Market Dynamics
  • Figure 8.30: Europe: Optical Biopsy Market (by Country), 2018-2030
  • Figure 8.31: Germany: Optical Biopsy Market, 2018-2030
  • Figure 8.32: U.K.: Optical Biopsy Market, 2018-2030
  • Figure 8.33: France: Optical Biopsy Market, 2018-2030
  • Figure 8.34: Netherlands: Optical Biopsy Market, 2018-2030
  • Figure 8.35: Rest-of-Europe: Optical Biopsy Market, 2018-2030
  • Figure 8.36: Europe: Other Technologies Market, 2018-2030
  • Figure 8.37: Europe: Other Technologies Market Dynamics
  • Figure 8.38: Europe: Other Technologies Market (by Country), 2018-2030
  • Figure 8.39: U.K: Other Technologies Market, 2018-2030
  • Figure 8.40: Germany: Other Technologies Market, 2018-2030
  • Figure 8.41: Switzerland: Other Technologies Market, 2018-2030
  • Figure 8.42: Asia-Pacific: Minimally Invasive Biopsy Technologies Market, 2018-2030
  • Figure 8.43: Asia-Pacific: Liquid Biopsy Market, 2018-2030
  • Figure 8.44: Asia-Pacific: Liquid Biopsy Market Dynamics
  • Figure 8.45: Asia-Pacific: Liquid Biopsy Market (by Country), 2018-2030
  • Figure 8.46: China: Liquid Biopsy Market, 2018-2030
  • Figure 8.47: Japan: Liquid Biopsy Market, 2018-2030
  • Figure 8.48: India: Liquid Biopsy Market, 2018-2030
  • Figure 8.49: Australia: Liquid Biopsy Market, 2018-2030
  • Figure 8.50: South Korea: Liquid Biopsy Market, 2018-2030
  • Figure 8.51: Singapore: Liquid Biopsy Market, 2018-2030
  • Figure 8.52: Rest-of-Asia-Pacific: Liquid Biopsy Market, 2018-2030
  • Figure 8.53: Asia-Pacific: Optical Biopsy Market, 2018-2030
  • Figure 8.54: Asia-Pacific: Optical Biopsy Market Dynamics
  • Figure 8.55: Asia-Pacific: Optical Biopsy Market (by Country), 2018-2030
  • Figure 8.56: Japan: Optical Biopsy Market, 2018-2030
  • Figure 8.57: China: Optical Biopsy Market, 2018-2030
  • Figure 8.58: South Korea: Optical Biopsy Market, 2018-2030
  • Figure 8.59: Rest-of-Asia-Pacific: Optical Biopsy Market, 2018-2030
  • Figure 8.60: Latin America and the Middle East: Minimally Invasive Biopsy Technologies Market, 2018-2030
  • Figure 8.61: Latin America and the Middle East: Liquid Biopsy Market, 2018-2030
  • Figure 8.62: Latin America and the Middle East: Liquid Biopsy Market Dynamics
  • Figure 8.63: Latin America and the Middle East: Liquid Biopsy Market (by Country), 2018-2030
  • Figure 8.64: Brazil: Liquid Biopsy Market, 2018-2030
  • Figure 8.65: Mexico: Liquid Biopsy Market, 2018-2030
  • Figure 8.66: Saudi Arabia: Liquid Biopsy Market, 2018-2030
  • Figure 8.67: Rest-of-Latin America and the Middle East: Liquid Biopsy Market, 2018-2030
  • Figure 8.68: Latin America and the Middle East: Optical Biopsy Market, 2018-2030
  • Figure 8.69: Rest-of-the-World: Minimally Invasive Biopsy Technologies Market, 2018-2030
  • Figure 8.70: Rest-of-the-World: Liquid Biopsy Market, 2018-2030
  • Figure 8.71: Rest-of-the-World: Optical Biopsy Market, 2018-2030
  • Figure 9.1: Abcodia Ltd.: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
  • Figure 9.2: Adaptive Biotechnologies: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
  • Figure 9.3: Adaptive Biotechnologies Net Revenue (by Business Segment), 2017 and 2018
  • Figure 9.4: Biocept, Inc.: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
  • Figure 9.5: Biocept, Inc.: Overall Financials, 2016-2018
  • Figure 9.6: Biocept, Inc.: R&D Expense, 2016-2018
  • Figure 9.7: Caliber Imaging & Diagnostics: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
  • Figure 9.8: Chronix Biomedical: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
  • Figure 9.9: DermTech: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
  • Figure 9.10: DermTech: Financials (Nine Months Ended September 2018-2019
  • Figure 9.11: DermTech: R&D Expense, 2016-2018
  • Figure 9.12: F. Hoffmann-La Roche Ltd: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
  • Figure 9.13: F. Hoffmann-La Roche Ltd: Overall Financials, 2016-2018
  • Figure 9.14: F. Hoffmann-La Roche Ltd Net Revenue (by Business Segment), 2016-2018
  • Figure 9.15: F. Hoffmann-La Roche Ltd: Net Revenue (by Region), 2016-2018
  • Figure 9.16: F. Hoffmann-La Roche Ltd: R&D Expense, 2016-2018
  • Figure 9.17: Guardant Health, Inc.: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
  • Figure 9.18: Guardant Health, Inc.: Overall Financials, 2016-2018
  • Figure 9.19: Guardant Health, Inc.: Net Revenue (by Segment), 2016-2018
  • Figure 9.20: Guardant Health, Inc.: Net Revenue (by Region), 2016-2018
  • Figure 9.21: Guardant Health, Inc.: R&D Expense, 2016-2018
  • Figure 9.22: Mauna Kea Technologies: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
  • Figure 9.23: Mauna Kea Technologies: Overall Financials, 2016-2018
  • Figure 9.24: Mauna Kea Technologies Net Revenue (by Activity), 2016-2018
  • Figure 9.25: Mauna Kea Technologies: Net Revenue (by Region), 2016-2018
  • Figure 9.26: Mauna Kea Technologies: R&D Expense, 2016-2018
  • Figure 9.27: Myriad Genetics: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
  • Figure 9.28: Myriad Genetics: Overall Financials, 2016-2018
  • Figure 9.29: Myriad Genetics Net Revenue (by Business Segment), 2016-2018
  • Figure 9.30: Myriad Genetics: R&D Expense, 2016-2018
  • Figure 9.31: NeoGenomics Laboratories, Inc.: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
  • Figure 9.32: NeoGenomics Laboratories, Inc.: Overall Financials, 2016-2018
  • Figure 9.33: NeoGenomics Laboratories, Inc. Net Revenue (by Business Segment), 2016-2018
  • Figure 9.34: NeoGenomics Laboratories, Inc.: R&D Expense, 2016-2018
  • Figure 9.35: Owlstone Medical Ltd: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
  • Figure 9.36: QIAGEN: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
  • Figure 9.37: QIAGEN: Overall Financials, 2016-2018
  • Figure 9.38: QIAGEN Net Revenue (by Product Category), 2016-2018
  • Figure 9.39: QIAGEN Net Revenue (by Customer Class), 2016-2018
  • Figure 9.40: QIAGEN Net Revenue (by Region), 2016-2018
  • Figure 9.41: QIAGEN: R&D Expense, 2016-2018
  • Figure 9.42: Thermo Fisher Scientific: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
  • Figure 9.43: Thermo Fisher Scientific: Overall Financials, 2016-2018
  • Figure 9.44: Thermo Fisher Scientific Net Revenue (by Business Segment), 2016-2018
  • Figure 9.45: Thermo Fisher Scientific: Net Revenue (by Region), 2016-2018
  • Figure 9.46: Thermo Fisher Scientific: R&D Expense, 2016-2018
  • Figure 9.47: Veracyte, Inc.: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
  • Figure 9.48: Veracyte, Inc.: Overall Financials, 2016-2018
  • Figure 9.49: Veracyte, Inc.: R&D Expense, 2016-2018